Mesothelioma Clinical Trials
Here are the 6 most popular medical studies for mesothelioma
Alkylating agents
Surgery + Chemotherapy + IMRT for Mesothelioma
This trial is testing a new, safer radiation therapy for people with a certain type of lung cancer. The old radiation therapy had lots of side effects, but the new one specifically targets the cancer and reduces the risk of damaging healthy tissue.
CAR T-cell Therapy
TIL Therapy for Advanced Cancer
This trial is testing a new treatment for cancer that involves removing some lymph nodes, infusing the patient with their own tumor cells, and then giving them a high dose of aldesleukin. The goal is to see if this can help patients with locally advanced, recurrent, or metastatic cancer.
Popular filter options for mesothelioma trials
NSCLC Clinical Trials
View 29 NSCLC medical studies.
CAR T-cell Therapy
Engineered T Cells + Pembrolizumab for Pleural Cancer
This trial is testing the safety of different doses of modified T cells for patients with malignant pleural disease. They will also test the combination of the T cells with another drug, pembrolizumab, to see what effect it has on the cancer.
Monoclonal Antibodies
Pembrolizumab + SO-C101 for Advanced/Metastatic Solid Tumors
This trial is testing a new drug, SO-C101, for safety and effectiveness in treating solid tumors. The trial will test the drug alone and in combination with another drug, pembrolizumab.
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
This trial is testing a new cell therapy for cancer that uses genetically engineered T cells. The T cells are modified to express two synthetic constructs: a single-domain antibody that recognizes human Mesothelin, and a PD-1:CD28 switch receptor. The PD-1:CD28 switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
Non-Small Cell Lung Cancer Clinical Trials
View 28 Non-Small Cell Lung Cancer medical studies.
CAR T-cell Therapy
Engineered T Cells + Pembrolizumab for Pleural Cancer
This trial is testing the safety of different doses of modified T cells for patients with malignant pleural disease. They will also test the combination of the T cells with another drug, pembrolizumab, to see what effect it has on the cancer.
Monoclonal Antibodies
Pembrolizumab + SO-C101 for Advanced/Metastatic Solid Tumors
This trial is testing a new drug, SO-C101, for safety and effectiveness in treating solid tumors. The trial will test the drug alone and in combination with another drug, pembrolizumab.
CAR T-cell Therapy
Cell Therapy for Mesothelioma
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.
CAR T-cell Therapy
TC-510 Cell Therapy for Cancer
This trial is testing a new cell therapy for cancer that uses genetically engineered T cells. The T cells are modified to express two synthetic constructs: a single-domain antibody that recognizes human Mesothelin, and a PD-1:CD28 switch receptor. The PD-1:CD28 switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
Metastatic Mesothelioma Clinical Trials
View 97 metastatic mesothelioma medical studies.
CAR T-cell Therapy
Engineered T Cells + Pembrolizumab for Pleural Cancer
This trial is testing the safety of different doses of modified T cells for patients with malignant pleural disease. They will also test the combination of the T cells with another drug, pembrolizumab, to see what effect it has on the cancer.
PD-L1 Positive Clinical Trials
View 6 PD-L1 positive medical studies.
Monoclonal Antibodies
Durvalumab + Chemotherapy for Mesothelioma
This trial will test a new treatment, durvalumab, for patients with malignant pleural mesothelioma who cannot have surgery to remove their tumor. Two-thirds of participants will receive durvalumab in addition to standard chemotherapy. Researchers hope that adding durvalumab to chemotherapy will improve patients' overall survival.
PD-1 Inhibitor
Pembrolizumab for Mesothelioma
This trial is testing how well pembrolizumab works in treating patients with malignant mesothelioma. Pembrolizumab is a monoclonal antibody that works by blocking PD-1, which may stimulate an immune response and kill tumor cells.
View More Mesothelioma Trials
See another 63 medical studies focused on mesothelioma.
Frequently Asked Questions
Introduction to mesothelioma
What are the top hospitals conducting mesothelioma research?
When it comes to advancing treatment options for mesothelioma, certain hospitals have emerged as leaders in clinical trials. Memorial Sloan Kettering Cancer Center in New york has taken the lead with ten ongoing trials and a total of 25 trials dedicated to this rare cancer. Their first recorded mesothelioma trial dates back to 2006, showcasing their commitment to pushing boundaries in research. Meanwhile, Massachusetts General Hospital in Boston has been making notable strides with eight active trials and a history of 17 completed studies since initiating their first mesothelioma trial in 2004.
Heading south to Houston, MD Anderson Cancer Center stands out with seven active clinical trials focused on mesothelioma and a cumulative total of 14 trials conducted thus far. They began their journey into researching this challenging condition in 2007. Similarly, Dana Farber Cancer Institute shares the spotlight with seven ongoing mesothelioma trials and an impressive record of 13 previously conducted studies since launching their inaugural trial in 2009.
Lastly but certainly not least is Mayo Clinic located in Rochester which also shoulders responsibility by conducting seven concurrent clinical tests for patients living with mesothelioma while contributing towards eleven prior investigations; they embarked on this journey just six years ago from2015.Mesothelioma presents its unique challenges due to its rarity and aggressive nature; however, these top-tier hospitals are forging ahead through innovative research efforts aimed at improving outcomes for those affected by this deadly disease.
Through collaboration between medical professionals across different locations and specialties, advancements are being made every day that bring us closer to finding more effective treatments or even potential cures for mesothelioma. The dedication displayed by these leading institutions highlights our collective determination to combat this challenging cancer head-on
Which are the best cities for mesothelioma clinical trials?
When it comes to mesothelioma clinical trials, several cities stand out as major hubs for research and treatment. New york City leads the way with 39 active trials investigating treatments like INBRX-109, ASTX295, and gavo-cel. Houston, Texas is also a prominent location with 37 ongoing studies focused on interventions such as Intensity-Modulated Radiation Therapy and NGM831. Boston, Massachusetts follows closely behind with 35 active trials exploring therapies like pembrolizumab and Lurbinectedin. Lastly, Los Angeles in California and Las Vegas in Nevada each offer 28 clinical trials examining various treatment approaches for mesothelioma patients. These cities provide individuals diagnosed with mesothelioma access to cutting-edge clinical trials that aim to improve outcomes and bring hope for better quality of life.
Which are the top treatments for mesothelioma being explored in clinical trials?
Mesothelioma, a challenging cancer to treat, is witnessing advancements in clinical trials as researchers explore potential breakthrough treatments. Leading the pack is pembrolizumab, with five active trials and an impressive 26 all-time mesothelioma trials since its introduction in 2015. Another contender making waves is LMB-100, which has shown promise with two ongoing trials and six total mesothelioma studies since its listing in 2016. Additionally, a pharmacological study has sparked interest with two active and three all-time mesothelioma trials recorded thus far. These innovative therapies offer hope for improved outcomes for patients battling this relentless disease.
What are the most recent clinical trials for mesothelioma?
Recent clinical trials for mesothelioma offer hope in the battle against this aggressive form of cancer. One promising trial is exploring a Part B Dose Expansion Combination, which aims to determine the effectiveness and safety of a new treatment approach for mesothelioma patients. Another study focuses on OT-101, investigating its potential benefits as a therapeutic option in mesothelioma cases. Additionally, researchers are evaluating the efficacy and tolerability of dose expansion strategies in solid tumors associated with mesothelioma. In another trial, magnesium sulfate is being investigated as a potential treatment option for managing symptoms related to this challenging disease. Furthermore, SynKIR-110 holds promise as an innovative therapy that could improve outcomes for those affected by mesothelioma. These recent clinical trials provide optimism and may pave the way towards more effective treatments for individuals battling this devastating condition.
What mesothelioma clinical trials were recently completed?
In the quest to combat mesothelioma, several clinical trials have recently concluded, showcasing significant progress in the field. Noteworthy among these is a trial sponsored by the University of Chicago that wrapped up in December 2021, examining the potential of Nivolumab as a treatment option. Another promising study was completed in July 2021 and focused on Magnesium Sulfate under the sponsorship of Dana-Farber Cancer Institute. Additionally, Epizyme, Inc., successfully completed a trial investigating Tazemetostat's efficacy against mesothelioma back in April 2020. These recent advancements highlight ongoing efforts to advance treatments for this challenging disease and offer hope to those affected by it.